Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

D’Ambrosio, L, Touati, N, Blay, J et al. (25 more authors) (2020) Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer. cncr.32795. ISSN 0008-543X

Abstract

Metadata

Authors/Creators:
  • D’Ambrosio, L
  • Touati, N
  • Blay, J
  • Grignani, G
  • Flippot, R
  • Czarnecka, AM
  • Piperno‐Neumann, S
  • Martin‐Broto, J
  • Sanfilippo, R
  • Katz, D
  • Duffaud, F
  • Vincenzi, B
  • Stark, DP https://orcid.org/0000-0002-6172-733X
  • Mazzeo, F
  • Tuchscherer, A
  • Chevreau, C
  • Sherriff, J
  • Estival, A
  • Litière, S
  • Sents, W
  • Ray‐Coquard, I
  • Tolomeo, F
  • Le Cesne, A
  • Rutkowski, P
  • Stacchiotti, S
  • Kasper, B
  • Gelderblom, H
  • Gronchi, A
Copyright, Publisher and Additional Information: © 2020 American Cancer Society. This is an author produced version of a paper published in Cancer. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Dacarbazine; doxorubicin; ifosfamide; leiomyosarcoma; sarcoma; propensity score; retrospective study
Dates:
  • Accepted: 24 January 2020
  • Published (online): 4 March 2020
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 23 Mar 2020 11:04
Last Modified: 27 Mar 2020 09:32
Status: Published online
Publisher: Wiley
Identification Number: https://doi.org/10.1002/cncr.32795

Download

Accepted Version


Embargoed until: 4 March 2021

Filename: R1 CNCR-19-2575 main manuscript clean final.pdf

Request a copy

Share / Export

Statistics